BioSpace News Archive

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2020. “Despite these unprecedented times, the first quarter was a period of important progress for Fulcrum and the fundamentals of our business remain strong,” said Robert J. Gould,

-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that Correlates Stabilization in Cardiac Function with a Reduction in a Biomarker of Cell Damage- -Company Planning to Meet with FDA to Discuss Pathway to Approval- -To Host Conference Call and Webcast Today at 8AM ET- LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a

GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer.

SOLIUS, a developer of innovative light therapy technologies focused on mitigating vitamin D deficiency, today announced investment from Human Longevity, Inc.

First quarter 2020 revenue of $130 million First quarter net loss of $9 million First quarter 2020 Adjusted EBITDA 1 of $63 million Generated cash flow from operations of $45 million in 2020 and concluded the quarter with a cash and cash equivalents balance of $266 million Announces the appointment of a Chief Medical Officer LONDON , May 13, 2020 /PRNewswir

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

Developed with Mayo Clinic, the algorithm helps identify low ejection fraction - a sign of heart failure and a significant comorbidity for COVID-19 patients OAKLAND, Calif.--( BUSINESS WIRE )-- Eko , a digital health company building AI-powered screening and telehealth solutions to fight cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has issued the company an Emergency Use Authorization (EUA) for its novel

QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion Leader (“KOL”) meeting to discuss the chronic cough landscape on Wednesday, May 27, 2020 at 9:00 a.m. EDT. The event will featur

CANTEL MEDICAL CORP. (NYSE: CMD) (“Cantel” or the “Company”) today announced the pricing of its offering of $140 million aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A un